Packaging & Product Protection Featured Articles

  1. Blister Package Integrity Testing Using Non-Destructive Methods

    Blister package manufacturing consists of plastic formed into cavities that house the tablet or the capsules and then sealed on the back with a lidding material (usually aluminum foil, paper or plastic).

  2. The Role Contract Manufacturers Play In Pharmaceutical Manufacturing And Packaging

    The pharmaceutical industry is changing at a rapid pace with a lot of trends and business relationships. This not only involves new medical developments, guidelines and corresponding equipment, but also the roles of all stakeholders. Uwe Harbauer, Senior Vice President of Bosch Packaging Technology’s Pharma Business Unit, shares his thoughts about the pharma marketing and relationships today.

  3. Blow/Fill/Seal Technology Automates Aseptic Vaccine Packaging

    Today, the trend with vaccine packaging is ready-to-administer single-dose packaging. Whether in the form of prefilled syringes or single-dose twist-off containers, this type of packaging offers safety, convenience, and cost benefits over traditional multidose vials.

  4. Container Closure Integrity Testing Of Complex Drug Delivery Systems

    New injection-delivery systems, such as auto-injectors, recombinant syringes, and retractable needles, have introduced new challenges, particularly for container closures.

  5. Six Myths About Serialization

    Expect that serialization mandates will govern most of world’s drug supply. Biopharmaceutical companies that don’t comply will find it impossible to market their drugs in countries that have instituted serialization regulations.

  6. Are You Prepared For The EU’s Falsified Medicines Directive?

    Given the complexities involved and time required for assessment and decision-making activities, it is imperative to start working toward meeting the EU’s Falsified Medicines Directive (FMD) standards immediately, leveraging previous efforts for compliance with other market regulations.

  7. The Right Biomanufacturing Partner Can Improve Flexibility And Mitigate Risks From Forecasting

    While forecasts can never be 100% accurate, the goal for biopharmaceutical forecasters should be to minimize the degree of inaccuracies as much as possible. To reduce the impact of inaccurate forecasting over the life cycle of a product, companies need to focus on those variables that they have the most control over.

  8. Operational Excellence In a Flexible Manufacturing Environment

    By thinking outside of the box, CDMOs can create a flexible and scalable business model that offers a level of assurance in the face of forecast variability.

  9. Establishing Best Practice Qualification Metrics For Smart Shipping Containers

    Wernher von Braun, the father of modern rocketry famously stated, “one test is worth a thousand expert opinions.” The FDA has put their own regulatory spin on this axiom: “if you didn’t document it; it didn’t happen.” This extends beyond the drug therapies themselves to the packaging and logistics practices that are used to distribute them; what the FDA refers to as the “holding” of a drug.

  10. BioMarin Transforms Supplier M&A Into Joint Ventures

    To navigate supplier and CMO consolidation, Isaac Young, senior director, supply chain operations, BioMarin Pharmaceutical Inc., offers some advice: Approach your outsourcing relationships like joint ventures. “As you have this greater engagement between two companies,” says Young, “you’re likely to enter an interdependent relationship. Why not acknowledge that rather than try to power-play or position one another?”